Trial of complete weaning from immunosuppression for liver transplant recipients: Factors predictive of tolerance

Recipients of liver transplantation (LT) may develop immunological tolerance. Factors predictive of tolerance are not clearly understood. Transplant recipients with normal liver function tests and without active viral hepatitis or autoimmune disease who presented with side effects of immunosuppression or a high risk of de novo malignancies were selected to participate in this prospective study. Twenty‐four patients fulfilled the inclusion criteria and, therefore, underwent a gradual reduction of immunosuppression. Tolerance was defined as normal liver function tests after immunosuppression withdrawal. Basal clinical and immunological characteristics, including lymphocyte counts and subpopulations (T, B, natural killer, CD4+, CD8+, and regulatory T cells) and the phytohemagglutinin stimulation index (SI), were compared for tolerant and nontolerant patients. Fifteen of the 24 patients (62.5%) were tolerant at a median of 14 months (interquartile range = 8.5‐22.5 months) after complete immunosuppression withdrawal. Tolerant patients had a longer median interval between transplantation and inclusion in the study (156 for tolerant patients versus 71 months for nontolerant patients, P = 0.003) and a lower median SI (7.49 for tolerant patients versus 41.73 for nontolerant patients, P = 0.01). We identified 3 groups of patients with different probabilities of tolerance: in the first group (n = 7 for an interval > 10 years and an SI < 20), 100% reached tolerance; in the second group (n = 10 for an interval > 10 years and an SI > 20 or an interval < 10 years and an SI < 20), 60% reached tolerance; and in the third group (n = 7 for an interval < 10 years and an SI > 20), 29% reached tolerance. In conclusion, a high proportion of select LT recipients can reach tolerance over the long term. Two simple basal variables—the time from transplantation and the SI—may help to identify these patients. Liver Transpl 19:937–944, 2013. © 2013 AASLD.

[1]  D. San Segundo,et al.  ImmuKnow as a diagnostic tool for predicting infection and acute rejection in adult liver transplant recipients: A systematic review and meta‐analysis , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[2]  A. Demetris.  Importance of liver biopsy findings in immunosuppression management: Biopsy monitoring and working criteria for patients with operational tolerance , 2012 .

[3]  C. Bellamy.  Importance of liver biopsy findings in immunosuppression management: biopsy monitoring and working criteria for patients with operational tolerance. , 2012, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[4]  Cedrik M. Britten,et al.  The development of standard samples with a defined number of antigen-specific T cells to harmonize T cell assays: a proof-of-principle study , 2012, Cancer Immunology, Immunotherapy.

[5]  P. Schroder,et al.  Can Immune Cell Function Assay Identify Patients at Risk of Infection or Rejection? A Meta-Analysis , 2012, Transplantation.

[6]  P. Rosenthal,et al.  Complete immunosuppression withdrawal and subsequent allograft function among pediatric recipients of parental living donor liver transplants. , 2012, JAMA.

[7]  D. Swinkels,et al.  Intra-graft expression of genes involved in iron homeostasis predicts the development of operational tolerance in human liver transplantation. , 2012, Journal of Clinical Investigation.

[8]  Sylvia Janetzki,et al.  Harmonization of Immune Biomarker Assays for Clinical Studies , 2011, Science Translational Medicine.

[9]  A. Sánchez‐Fueyo.  Hot‐topic debate on tolerance: Immunosuppression withdrawal , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[10]  J. Lozano,et al.  Comparison of Transcriptional and Blood Cell‐Phenotypic Markers Between Operationally Tolerant Liver and Kidney Recipients , 2011, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[11]  B. Sangro,et al.  Risk factors of lung, head and neck, esophageal, and kidney and urinary tract carcinomas after liver transplantation: The effect of smoking withdrawal , 2011, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[12]  M. Olausson,et al.  Conversion from calcineurin inhibitor to either mycophenolate mofetil or sirolimus improves renal function in liver transplant recipients with chronic kidney disease: results of a prospective randomized trial. , 2010, Transplantation proceedings.

[13]  A. Sánchez‐Fueyo,et al.  Minimization of immunosuppression in adult liver transplantation: new strategies and tools , 2010, Current opinion in organ transplantation.

[14]  W. Kremers,et al.  Evolution of Causes and Risk Factors for Mortality Post‐Liver Transplant: Results of the NIDDK Long‐Term Follow‐Up Study , 2010, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[15]  S. Tomé,et al.  Improvement of renal function after conversion to mycophenolate mofetil combined with low-level calcineurin inhibitor in liver transplant recipients with chronic renal dysfunction. , 2010, Transplantation proceedings.

[16]  Yun-Ling Zheng,et al.  Phytohemagglutinin-Induced Mitotic Index in Blood Lymphocytes: A Potential Biomarker for Breast Cancer Risk , 2010, Breast cancer : basic and clinical research.

[17]  J. Herrero.  De novo malignancies following liver transplantation: Impact and recommendations , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[18]  J. Neuberger.  What is the real gain after liver transplantation? , 2009, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[19]  P. Parrilla,et al.  Immunosuppression withdrawal improves long‐term metabolic parameters, cardiovascular risk factors and renal function in liver transplant patients , 2009, Clinical transplantation.

[20]  S. Soker,et al.  Operational tolerance after liver transplantation. , 2009, Journal of hepatology.

[21]  K. Stone,et al.  Analysis of in vitro lymphocyte proliferation as a screening tool for cellular immunodeficiency. , 2009, Clinical immunology.

[22]  P. Parrilla,et al.  FoxP3 in Peripheral Blood Is Associated With Operational Tolerance in Liver Transplant Patients During Immunosuppression Withdrawal , 2008, Transplantation.

[23]  P. Parrilla,et al.  Using transcriptional profiling to develop a diagnostic test of operational tolerance in liver transplant recipients. , 2008, The Journal of clinical investigation.

[24]  Y. Avitzur,et al.  ImmuKnow: A new parameter in immune monitoring of pediatric liver transplantation recipients , 2008, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[25]  S. Brouard,et al.  Spontaneous Operational Tolerance After Immunosuppressive Drug Withdrawal in Clinical Renal Allotransplantation , 2007, Transplantation.

[26]  N. Assy,et al.  Randomized Controlled Trial of Total Immunosuppression Withdrawal in Liver Transplant Recipients: Role of Ursodeoxycholic Acid , 2007, Transplantation.

[27]  M. Ramoni,et al.  Multiparameter Immune Profiling of Operational Tolerance in Liver Transplantation , 2007, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[28]  G. Tisone,et al.  Operational tolerance in clinical liver transplantation: emerging developments. , 2007, Transplant immunology.

[29]  G. Tisone,et al.  Complete weaning off immunosuppression in HCV liver transplant recipients is feasible and favourably impacts on the progression of disease recurrence. , 2006, Journal of hepatology.

[30]  J. Moon,et al.  The Role of Donor Bone Marrow Infusions in Withdrawal of Immunosuppression in Adult Liver Allotransplantation , 2005, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[31]  T. Fehr,et al.  Tolerance induction in clinical transplantation. , 2004, Transplant immunology.

[32]  G. Loss,et al.  Tolerance: Is It Worth the Risk? , 2005, Transplantation.

[33]  J. Prieto,et al.  Prognostic model for early acute rejection after liver transplantation , 2001, Liver transplantation : official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.

[34]  R. Wiesner,et al.  Acute hepatic allograft rejection: Incidence, risk factors, and impact on outcome , 1998, Hepatology.

[35]  B. Portmann,et al.  Defining the outcome of immunosuppression withdrawal after liver transplantation , 1998, Hepatology.

[36]  T. Starzl,et al.  Weaning of immunosuppression in liver transplant recipients. , 1997, Transplantation.

[37]  R. Wiesner,et al.  Long-term outcome after liver transplantation. , 1989, Transplantation proceedings.

[38]  P. Medawar,et al.  ‘Actively Acquired Tolerance’ of Foreign Cells , 1953, Nature.

[39]  T. Strom,et al.  Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. , 2011, Gastroenterology.

[40]  高槻 光寿.  Weaning of immunosuppression in living donor liver transplant recipients , 2002 .